CERAMENT® G approved for Transitional Pass-Through payment (TPT)
Kurs
-1,91%
Likviditet
12,0 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2025-10-23 | 08:00 | Kvartalsrapport 2025-Q3 |
| 2025-07-15 | 08:00 | Kvartalsrapport 2025-Q2 |
| 2025-05-28 | N/A | X-dag ordinarie utdelning BONEX 0.00 SEK |
| 2025-05-27 | N/A | Årsstämma |
| 2025-04-24 | - | Kvartalsrapport 2025-Q1 |
| 2025-02-25 | - | Bokslutskommuniké 2024 |
| 2024-10-24 | - | Kvartalsrapport 2024-Q3 |
| 2024-07-11 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-17 | - | X-dag ordinarie utdelning BONEX 0.00 SEK |
| 2024-05-16 | - | Årsstämma |
| 2024-04-25 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-15 | - | Bokslutskommuniké 2023 |
| 2023-10-26 | - | Kvartalsrapport 2023-Q3 |
| 2023-07-13 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-19 | - | X-dag ordinarie utdelning BONEX 0.00 SEK |
| 2023-05-17 | - | Årsstämma |
| 2023-04-27 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-16 | - | Bokslutskommuniké 2022 |
| 2022-10-27 | - | Kvartalsrapport 2022-Q3 |
| 2022-07-14 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-20 | - | X-dag ordinarie utdelning BONEX 0.00 SEK |
| 2022-05-19 | - | Årsstämma |
| 2022-05-04 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-17 | - | Bokslutskommuniké 2021 |
| 2021-11-04 | - | Kvartalsrapport 2021-Q3 |
| 2021-07-15 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-21 | - | X-dag ordinarie utdelning BONEX 0.00 SEK |
| 2021-05-20 | - | Årsstämma |
| 2021-05-06 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-17 | - | Bokslutskommuniké 2020 |
| 2020-11-05 | - | Kvartalsrapport 2020-Q3 |
| 2020-07-17 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-20 | - | X-dag ordinarie utdelning BONEX 0.00 SEK |
| 2020-05-19 | - | Årsstämma |
| 2020-05-08 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-26 | - | Bokslutskommuniké 2019 |
| 2019-11-07 | - | Kvartalsrapport 2019-Q3 |
| 2019-07-25 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-15 | - | X-dag ordinarie utdelning BONEX 0.00 SEK |
| 2019-05-14 | - | Årsstämma |
| 2019-05-02 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-27 | - | Bokslutskommuniké 2018 |
| 2018-11-07 | - | Kvartalsrapport 2018-Q3 |
| 2018-07-26 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-23 | - | X-dag ordinarie utdelning BONEX 0.00 SEK |
| 2018-05-22 | - | Årsstämma |
| 2018-05-04 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-20 | - | Bokslutskommuniké 2017 |
| 2017-11-02 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-17 | - | Kvartalsrapport 2017-Q2 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Large Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announces that the American Centers for Medicare & Medicaid Services (CMS) have approved CERAMENT G for the Transitional Pass-Through (TPT) payment as part of the 2024 Medicare Hospital Outpatient Prospective Payment System.
CERAMENT G has been approved for TPT for the indication bone infection, under the alternative pathway for devices that have received both breakthrough device designation and marketing authorization by the American Food and Drug Administration (FDA). The TPT payment will be effective on January 1, 2024 and will provide outpatient facilities with incremental Medicare payment for CERAMENT G for at least two years.
The TPT payment is intended to reimburse hospitals and ambulatory surgical centers for the incremental cost of new and innovative technologies such as CERAMENT G in the outpatient setting.
CMS has previously granted CERAMENT G with the New Technology Add-on Payment (NTAP), which provides additional payment in the hospital inpatient setting.
For more information contact:
BONESUPPORT Holding AB
Emil Billbäck, CEO
+46 (0) 46 286 53 70
Håkan Johansson, CFO
+46 (0) 46 286 53 70
ir@bonesupport.com
Cord Communications
Charlotte Stjerngren
+46 (0) 708 76 87 87
charlotte.stjerngren@cordcom.se
www.cordcom.se
About BONESUPPORT™
BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 329 million in 2022. Please visit www.bonesupport.com for more information.
BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.